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Abstract
Background: The Tensin family of intracellular proteins (Tensin1, -2, -3 and -4) are thought to act as links between the
extracellular matrix and the cytoskeleton, and thereby mediate signaling for cell shape and motility. Dysregulation of Tensin
expression has previously been implicated in human cancer. Here, we have for the first time evaluated the significance of all
four Tensins in a study of human renal cell carcinoma (RCC), as well as probed the biological function of Tensin3.
Principal Findings: Expression of Tensin2 and Tensin3 at mRNA and protein levels was largely absent in a panel of diverse
human cancer cell lines. Quantitative RT-PCR analysis revealed mRNA expression of all four Tensin genes to be significantly
downregulated in human kidney tumors (50–100% reduction versus normal kidney cortex; P,0.001). Furthermore, the
mRNA expressions of Tensins mostly correlated positively with each other and negatively with tumor grade, but not tumor
size. Immunohistochemical analysis revealed Tensin3 to be present in the cytoplasm of tubular epithelium in normal human
kidney sections, whilst expression was weaker or absent in 41% of kidney tumors. A subset of tumor sections showed a
preferential plasma membrane expression of Tensin3, which in clear cell RCC patients was correlated with longer survival.
Stable expression of Tensin3 in HEK 293 cells markedly inhibited both cell migration and matrix invasion, a function
independent of putative phosphatase activity in Tensin3. Conversely, siRNA knockdown of endogenous Tensin3 in human
cancer cells significantly increased their migration.
Conclusions: Our findings indicate that the Tensins may represent a novel group of metastasis suppressors in the kidney,
the loss of which leads to greater tumor cell motility and consequent metastasis. Moreover, tumorigenesis in the human
kidney may be facilitated by a general downregulation of Tensins. Therefore, anti-metastatic therapies may benefit from
restoring or preserving Tensin expression in primary tumors.
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Introduction
The Tensins constitute a family of intracellular proteins that are
coming to the fore as novel regulators of cell motility and growth.
The Tensin family is composed of four members: Tensin1,
Tensin2, Tensin3 and Tensin4 (TNS1, TNS2, TNS3, TNS4) each
with discrete expression patterns in the human body [1,2]. Based
on their common domains, the Tensins have the potential to
interact with the plasma membrane (C1 domain) as well as bind to
tyrosines (SH2 and PTB domain) in integrins [3] and receptor
tyrosine kinases (RTKs) [1].
In addition, Tensins 1-3, but not -4, contain a phosphatase
(PTPase)-C2 domain pair that is homologous to that in the PTEN
tumour suppressor protein [4,5]. However, the potential lipid
PTPase activity of Tensins 1–3, as well as their putative
interactions with the actin cytoskeleton, remains to be determined.
Tensin1 was the first member identified, and is localized to focal
adhesions in cells [6]. We identified Tensin2 (also known as C1-
TEN, TENC1) as a binding partner for Axl RTK through its
SH2-PTB region [1]. Tensin3 has virtually the same domain
organization as C1-TEN, and interacts with the EGF receptor [7].
Tensin4 is a shorter protein that is not expected to interact with
the cytoskeleton, whilst it contains the SH2-PTB domains similar
to the other Tensins [8].
The functional consequence of Tensin interactions suggests
regulation of membrane receptor signaling that is linked to control
of cytoskeletal dynamics. This therefore has implications for cell
motility in the metastatic process. For example, in breast cancer
cells, Tensin3 was shown to anchor integrins to the cytoskeleton,
rendering the cell less motile and thereby less capable of
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factor (EGF) upregulates Tensin4, which is a shorter protein that
could lack actin-binding regions but which still interacts with
integrins. This mobilization of Tensin4 results in its displacement
of Tensin3 from the integrin, thus destabilizing the cytoskeleton
and enhancing cell motility. We have reported that Tensin2
expression in kidney cells inhibits cell proliferation, survival and
migration, concomitant with a selective suppression of the Akt
signaling pathway [5]. Finally, an interaction apparently common
to all four Tensins is that with the DLC-1 tumor suppressor
protein, which may be a mediator for the potential anti-tumor
effects of Tensins [10–12].
In the United States, 54390 new cases of renal cancer are
predicted to occur in 2008, causing an estimated 13010 deaths
[13]. Renal cell carcinoma (RCC) is a cancer originating from
kidney epithelium and accounts for 85% of kidney cancers and
associated mortality. RCC can be further subdivided into different
subtypes: conventional or clear cell RCC (ccRCC), which
represents the large majority of RCC cases, followed by papillary
(pRCC) and chromophobe (chRCC). Also included in this study is
oncocytoma, which is a non-RCC, benign tumor type. Each of
these tumor types has a distinct pathogenesis. For example, two
thirds of ccRCC cases are linked with a defect in the von Hippel-
Lindau (VHL) tumor suppressor gene [14].
However, the epithelial cell transformation that occurs in
common to these tumor types involves multiple processes,
including mutations that enable conditions favorable for cancer
cell survival, proliferation and migration. In addition, enhanced
cancer cell motility is a principal feature in the early metastatic
process. As a quarter of RCC patients present with locally invasive
or metastatic disease, it is imperative to identify the factors and
mechanisms that underlie the metastatic process.
The kidney is the organ where most Tensins are preferentially
expressed [1,6,7]. Deletion of the Tensin2 gene was shown to be
behind a mouse model of nephrotic syndrome [15], and knockout
mice for Tensins -1 and -3 exhibit kidney tubular cyst formation
and renal failure [16,17]. Therefore, there is a distinct need to
investigate the Tensins for their expression and functions in the
human kidney in both normal and disease states. The aim of the
present study was to investigate the role of the entire Tensin family
in human RCC.
Methods
Cell culture
The following human cancer cell lines were cultured and
prepared for qRT-PCR and western blot analysis: breast (MCF-7,
MDA-MB231), prostate (DU145, PC3, PNT-1A), colorectal
adenocarcinoma (SW480), cervical carcinoma (HeLa S3), osteo-
sarcoma (U20S), melanoma (WM9, WM266-4, WM793), non-
small lung cancer (H358, H2087, H226, H727) and B cell
lymphoma (U629, U2932). Various human non-cancer cell lines
were also analyzed: endothelial cell line (EAhy926), dermal
fibroblasts (AG52), kidney proximal tubular cells (HK-2), breast
epithelial cells (MCF-10A). Cells were grown in DMEM
supplemented with 10% fetal bovine serum, 20 mM glutamine,
100 U/ml penicillin and 100 mg/ml streptomycin at 37uCi na
humidified atmosphere of 5% CO2 in air.
Patients
The study included 260 patients with histopathologically
verified renal cell carcinoma (RCC) after nephrectomy performed
at the Department of Urology, Umea ˚ University Hospital,
between 1982–2003. The study was approved by the ethical
committee of Umea ˚ University and by the Institutional Review
Board, and each patient participated after providing informed
consent. The clinicopathological characteristics of the patients are
summarized in Table 1.
Staging procedures included a physical examination, chest
radiography, ultrasonography and computerized tomography of
the abdomen. Tumors were staged according to the TNM
classification system 2002 [18] and histopathological grading was
done according to Skinner et al. [19]. The RCC type was defined
according to the Heidelberg consensus conference [20]. Tumor
size was measured on the surgical specimens and/or on
computerized tomography. Tumor size varied from 0.6 cm to
25 cm (median: 7.0 cm). Venous invasion was defined as tumor
invasion in major renal veins, verified microscopically in tissue
slices from the renal hilum. Patient follow-up status was assessed at
least yearly by routine clinical follow-up at Umea ˚ University
Hospital or by contacting patients directly. During the follow-up
period, among the 260 patients, 139 had died of the disease, 61
had died from other causes, 7 were alive with disease, and 53 were
alive and free of disease. Tumor and kidney cortex tissue were
sampled immediately after the nephrectomy. Samples from
histopathologically nonmalignant kidney cortex tissue remote
from the tumor zone were also obtained from 48 patients and
used for comparative evaluation.
Electrophoresis and western blot
Cells were lysed in lysis buffer (1% NP-40, 1% deoxycholate,
5 mM EDTA, 1 mM EGTA in PBS, pH 7.4) and separated on
5% and 8% polyacrylamide SDS gels under reducing conditions
and then transferred to a PVDF membrane. Membranes were
blocked in 3% fish gelatin in 0.1 M Tris-HCl, pH 8.0, 1.5 M
NaCl and 0.5% Tween 20 (washing buffer), probed with a primary
antibody against Tensin2 (1:1000 dilution) and Tensin3 (1:1000),
respectively, for 1 h, washed with washing buffer followed by
incubation for 1 h with the secondary antibody linked to either
horseradish peroxidase (HRP) or alkaline phosphatase (AP).
Afterwards, the membranes were visualized by a chemilumines-
cence method (HRP) or by the reduction of the 4-nitroblue
tetrazolium salt (NBT) in the presence of 5-bromo-4 chloro-3
indol-phosphate (BCIP) in 0.1 M Tris-HCl, 0.05 M MgCl2, 0.1 M
NaCl, pH 9.5 (AP).
Antibodies used for detection of Tensin2 and Tensin3 were both
in-house rabbit polyclonal antibodies generated against peptides
Table 1. Clinicopathological variables for renal cell carcinoma
patients in this study.
Factor Distribution
Number of patients 260
Patient sex M/F 156/104
Mean patient age 66 (range 25–85)
Tumor size 6–250 (median 70) mm
Tumor grade 1/2/3/4 13/48/129/61
TNM stage I/II/III/IV 66/42/64/79
Tumor type ccRCC/pRCC/chRCC/oncocytoma 205/30/13/8
Tumor type ccRCC/pRCC/chRCC/oncocytoma as
source of matched normal tissue
36/7/3/2
Venous invasion no/yes 157/103
Regional lymph-node involvement no/yes 65/29
doi:10.1371/journal.pone.0004350.t001
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antisera were purified sequentially, first by affinity chromatogra-
phy on protein A and G sepharose columns and subsequent
further affinity purification using the immobilized peptide
antigens, as previously described for anti-Tensin2 [5]. Anti-
Tensin3 antibodies were tested for specificity using cell lysates
expressing full-length recombinant Tensin3, as well as by blocking
with the Tensin3 C-terminal peptide antigen (Figure S1). A
commercial rabbit polyclonal anti-Tensin3 antibody (Sigma) was
employed for western blots of stably transfected Tensin3 cell
lysates. Optimal dilutions were determined for western blotting.
Real-time quantitative reverse transcription-PCR (qRT-
PCR)
For qRT-PCR analysis of kidney cancer patient samples, the
viable area of each tumor tissue was used to obtain high-quality
RNA, extracted using TRIzol reagent (Invitrogen, Stockholm,
Sweden). From cultured cells, total RNA was extracted using
CellDirect
TM One-Step qRT-PCR Kit (Invitrogen, Lidingo ¨,
Sweden). RNA concentrations were quantified by spectrophoto-
metric measurement at 260 nm wavelength (DU640 spectropho-
tometer, Beckman Coulter, Bromma, Sweden) and RNA integrity
was verified by ethidium bromide staining of 28S and 18S rRNA
after agarose gel electrophoresis.
One-step multiplex real-time quantitative RT-PCR was em-
ployed, where amplification of both the gene of interest and
endogenous control gene were performed together in the same
reaction tube. Gene-specific primers and Taqman probes were
purchased from Applied Biosystems (Applera Sweden, Stockholm,
Sweden). For each sample, 40 ng of total RNA was mixed with a
reverse transcriptase and polymerase enzyme master mix, and
TaqManH MGB probes and primers were added to this mix to a
final volume of 25 ml. The qRT-PCR reaction was performed in
an ABI PRISM 7900HT system (Applera Sweden, Stockholm,
Sweden), employing the following cycling conditions: reverse
transcription for 15 min at 50uC; 2 min at 95uC, and 40 cycles of:
95uC for 15 sec and 60uC for 60 sec. Each measurement was
performed in duplicate and the threshold cycle (Ct) was
determined for each amplification curve.
In order to generate standard curves for quantitative analysis of
each gene, a cell line was chosen that was a reliable and verified
source of mRNA for that particular gene. RNA template was
omitted in negative controls, and a standard curve from serial
dilutions of total RNA from the relevant cell line was obtained for
all runs and each gene of interest. For each sample, the mean of
duplicate Ct values was converted to ng RNA from linear
regression analysis using a relative standard curve method using
Excel package (Microsoft, Redmond, Washington). Each deter-
mined RNA value was then normalized for the endogenous
reference gene content of the same sample. From a screen of 11
candidate housekeeping genes, the human b2-microglobulin
(B2M) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
genes were empirically determined by us to be the most robust
endogenous control genes for human kidney tissue and human cell
lines, respectively (data not shown). Results obtained were
arbitrarily expressed as ng Tensin RNA/ng endogenous control
RNA.
Northern blot analysis
Human multiple tissue Northern (MTN) blots (BD Biosciences,
Stockholm, Sweden), containing 2 mg poly A+ RNA each from
eight cancer cell lines, were probed for expression of Tensin2
mRNA. A 1.6 kb 3-terminal cDNA sequence common to all splice
variants of Tensin2 was used as
32P-labelled probe. The cDNA
sequence for human b-actin was used as a control probe.
Radiolabeling with [
32P]dCTP was achieved through the
Rediprime II DNA labeling system (GE Healthcare, Uppsala,
Sweden). Hybridization was carried out overnight at 42uCi n
ULTRAhyb hybridization buffer (Ambion, Stockholm, Sweden),
followed by high stringency washes. Membranes were exposed to a
Phosphor-Imager screen at least overnight prior to vizualization.
Immunohistochemical analysis of Tensin3 in human
kidney tumors
For the construction of tissue microarrays (TMAs), RCC sections
were collected as described above, and screened by primary
evaluation of hematoxylin/eosin-stained slides before TMA prep-
aration as described previously [21]. Briefly, two 0.6 mm diameter
tissue cores were collected from each tumour block and arranged in
a recipient block using a manual tissue arrayer (Beecher Inc., Sun
Prairie, WI). TMA sections at 4 mm thickness were deparaffinized
and microwave treated for antigen retrieval according to standard
procedures. The quality and robustness of the RCC TMA has been
tested for other factors and reported by us previously [22]. The
rabbit polyclonal anti-Tensin3 antibody used for TMA immuno-
staining is described above and was verified for specificity from
analysis of mock- and Tensin3-transfected cells as well as by antigen
blocking (Figure S1). For immunostaining, the antibody was used at
an optimally determined dilution of 1:300. Detection was
performed with horseradish peroxidase using the Dako EnVision
and TechMate 500 systems, and counterstaining with hematoxylin
and eosin. TMA sections from 148 patients were analyzed and
staining was grouped into no, low, medium, or high expression of
Tensin3, as well as additionally for presence or absence of staining
at the plasma membrane (PM). All TMAs were evaluated
independently by two observers.
Generation of recombinant Tensin3-expressing cells
The complete cDNA sequence for Tensin3 (1409 amino acids;
NCBI accession no. NM_022748) was cloned into pcDNA3
mammalian expression vector (Gibco Invitrogen, Lidingo ¨, Sweden)
for stable expression in human embryonic kidney (HEK) 293 cells, as
previously described [5]. Plasmid-bearing cells were selected for
growth in the presence of the neomycin analog G418 (400 mg/ml).In
parallel, mock-transfected cell clones were also developed bearing
empty vector only, as well as mutant clones containing a putative
PTPase-dead mutant Tensin3 (Tns3 Mut) cDNA. This mutant was
generated in the putative PTPase active site of Tensin3 with cysteine
at position 107 substituted for a serine. Mutation of the wildtype
T e n s i n 3c D N Ai np c D N A 3v e c t o rw a sp e r f o r m e db yQ u i k C h a n g e
site-directed mutagenesis (Stratagene, Amsterdam, The Netherlands)
according to the manufacturer’s instructions, using the following
primers (switched nucleotide underlined): 59-CATGTGGTCGT-
CATTCACAGCAGGGGCGGGAAAGGAC-39 (sense) and 59-
GTCCTTTCCCGCCCCTGCTGTGAATGACGACCACATG-
39 (antisense).
Cell proliferation assays
Cell proliferation was assessed in two ways. The first was
measurement of mitochondrial activity as a reflection of viable cell
number, as previously described [23]. Briefly, separate clones of
stably transfected mock 293 cells, wildtype Tensin3 cells (Tns3 wt)
and Tensin3 PTPase mutant cells (Tns3 Mut) were seeded sparsely
at 0.5610
4 cells per well in a 96-well microtiter plate, in medium
containing 0.5% serum (day 21). The next day (day 0), the
medium was replaced with that containing 5% serum, and cells
were further incubated for up to 7 days. On each successive day,
Tensins in Human Kidney Cancer
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during 3 h of the tetrazolium compound [3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazoli-
um (MTS, Sigma) into a soluble formazan product that was
measured spectrophotometrically at 490 nm. Quadruplicate wells
were used for each measurement.
The second method for cell proliferation was quantitation of
absolute cell numbers to generate a growth curve over 5 days.
Separate clones of stably transfected mock 293 cells, wildtype
Tensin3 cells (Tns3 wt) and Tensin3 PTPase mutant cells (Tns3
Mut) were seeded at 1610
4 cells per well in a 48-well plate, in
medium containing 0.5% serum (day 21). The next day (day 0),
the medium was replaced with that containing 5% serum, and
cells were incubated for a further 5 days. On each successive day,
cell number per well was determined by trypsinization of cells
from the wells and counting in a hemocytometer chamber. For
each clone, the cell number was determined from the mean count
from nine fields. In both experiments, statistical differences
between cell types on each day were determined by ANOVA
with Bonferroni post-hoc correction.
Cell migration and cell matrix invasion assays
A modified Boyden chamber assay system was used to
determine migration/haptotaxis of Tensin3–transfected cells as
previously described [5]. Briefly, cell culture inserts with 8 mm
pore size membranes (Nunclon, Roskilde, Denmark) were pre-
coated with fibronectin (10 mg/ml; Sigma, Stockholm, Sweden) on
the underside. Inserts were placed into wells of 24-well plates
containing complete growth medium, and 10
5 cells were seeded
into each insert interior in complete medium. Duplicate inserts
were used for each separate cell line analyzed. Cells were allowed
to migrate at 37uC in a cell culture incubator for 18 h. Afterwards,
inserts were removed and medium inside aspirated. All cells left on
the upper surface of the membrane were wiped away and insert
membranes were briefly rinsed, fixed in 10% formalin and stained
with Gram’s crystal violet solution (Fluka, Stockholm, Sweden).
Cells from a minimum of three high power fields per insert were
counted under light microscopy (Olympus, Solna, Sweden).
Statistical comparisons between migration of individual cell clones
were carried out by ANOVA with Bonferroni post-hoc correction.
For matrix invasion assays, the haptotaxis assay above was
modified such that instead of fibronectin, the basement membrane
matrix mixture Matrigel (BD Biosciences, Bedford, MA) was used
to cover the upper side of cell culture inserts with 8 mm pores.
Separate clones of Mock and Tensin3-transfected 293 cells were
seeded into the chamber interiors in medium containing 0.5%
serum, whilst the wells of 24-well plates contained complete
growth medium, thereby creating a serum gradient. Duplicate
inserts were used for each separate cell line analyzed. Cells were
allowed to invade the matrix and migrate through to the other side
of the membrane over 30 h at 37uC. Afterwards, cells were fixed,
stained and counted as described above.
Knockdown of Tensin3 by siRNA silencing
The melanoma cell line WM793 was selected for Tensin3 gene
silencing as it expressed the highest amounts of Tensin3 out of all
the cancer cell lines tested (Figure 1B). Cells were seeded in 6-well
plates 24 h prior to siRNA transfection. Cells were separately
transfected with 5 nM each of three different Tensin3 siRNA
constructs, siRNA I, II (ON-TARGET plus siRNA Reagents;
Dharmacon, Ta ¨by, Sweden) and III (HP validated siRNA;
Qiagen, Solna, Sweden). Negative controls included transfection
mixture only and a non-silencing siRNA that was shown to have
little effect on global gene expression (AllStars; Qiagen, Solna,
Sweden). The siRNA was mixed with Lipofectamine 2000 and
OptiMEM I serum free medium (Invitrogen, Lidingo ¨, Sweden),
and the tranfection mixture was incubated with cells for 24 h.
After this period, cells were trypsinized, counted and subjected to a
migration/haptotaxis assay exactly as described above, except that
0.5610
5 WM793 cells per insert were used, and migration was
allowed to occur over 16 h.
Statistical analysis
All clinical data were analyzed using the SPSS software package
(version 16.0.2 for Macintosh; SPSS Institute, Chicago, IL). Mean
differences of non-normally distributed data were analyzed by the
Mann-Whitney test. The Kruskal-Wallis test was used for
comparison between more than two groups. Correlations were
assessed by Spearman rank correlation test. Survival curves were
evaluated with the Kaplan-Meier method and survival times were
compared using the log-rank test.
In cell proliferation, migration and invasion assays, statistical
comparisons between different cell clones or treatments were
carried out by ANOVA with Bonferroni post-hoc correction. All
statistical tests were two-sided and a P value of less than 0.05 was
considered to be statistically significant.
Results
Tensin expression is largely absent in human cancer cell
lines
We first screened a panel of human cancer cell lines for Tensin
expression. A selection of different human cancer cell lines was
screened by Northern blot analysis for expression of Tensin2
mRNA. The expected band at 5 kb for Tensin2, as previously
reported in human organs [1], was barely detectable in only 2 out
of 8 cell lines: HeLa and SW480 (Figure 1A). We went on to
perform quantitative RT-PCR to further investigate mRNA
expression levels of Tensin2 and Tensin3 in a larger selection of
human cancer cell lines and compared them directly to RNA
extracted from whole human kidney tissue extracts. As shown in
Figure 1B, Tensin2 mRNA was absent in the majority of cell lines.
Only the colorectal adenocarcinoma cell line SW480 expressed
Tensin2 mRNA at detectable levels, which was also seen in the
Northern blot (Figure 1A). Significantly, both Tensin2 and
Tensin3 expression were lower in a single RCC patient’s kidney
tumor extract as compare to its adjacent normal counterpart
(matched). The results show that Tensin3 expression is higher and
broader than that of Tensin2 amongst the investigated cell lines,
but that both genes appear to be downregulated in RCC. We also
examined Tensin1 and Tensin4 mRNA in the same panel of
samples and found expression of these Tensins to be largely
undetectable or totally absent (data not shown).
We performed immunoblot to analyze the protein expression of
Tensin2 and Tensin3 (Figure 1C, D). In keeping with the mRNA
results, expression of Tensin2 at the protein level (molecular
weight 160 kDa) was hardly detected in human cancer cell lines,
whereas Tensin3 (180 kDa) expression was detectable at least in
two cell lines: melanoma cell line WM793 and lung carcinoma line
H727. Together these results show that expression of all Tensins is
largely absent in human cancer cell lines as well as being
downregulated in human kidney tumors.
Tensins 1–4 mRNA levels are significantly lower in renal
cell carcinoma versus normal kidney tissue
We applied multiplex one-step qRT-PCR to evaluate mRNA
expression levels of all four Tensins in this clinical study of total
RNA extracted from 223 RCC and 48 normal kidney cortex tissue
Tensins in Human Kidney Cancer
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patients in this study are shown in Table 1. The normal samples
were obtained from matched tumor sources and the distribution of
tumor types amongst these was similar to that in the overall
population, ie. 75% were of clear cell type (Table 1). From a
screen of 11 candidate housekeeping genes (Applera Sweden,
Stockholm, Sweden), we empirically determined the B2M gene to
be the most consistent and robust internal standard to use for
human kidney tissue (data not shown).
As shown in Figure 2A, mRNA expression of Tensin2 from 223
RCC extracts was significantly lower than in extracts from normal
kidney cortex (48 cases; p,0.001). The results are largely reflected
from ccRCC, which represented the majority of cases; however
the lower levels in pRCC were also of high significance (p,0.001).
Furthermore, analysis of only the subgroup of tumor material that
had matched normal counterparts yielded also a significantly
lower Tensin2 and -3 expression in the tumor tissues (n=48;
p,0.001). In addition, there was also a statistically significant drop
in Tensin1 expression in tumor samples (n=134) compared to
normals (n=21) (Figure 2B). A similar and highly significant
reduction in Tensin3 mRNA expression was also observed
(Figure 2C). Notably, Tensins -1, -2 and -3 expression was
detected in all samples measured. In contrast, Tensin4 expression
was largely absent in the majority of RCC samples measured
(n=134), whilst it was present in all normal kidney cortex samples
(n=21) (Figure 2D). These findings, in conjunction with those
described above, show that a general drop in the expression of
Tensins occurs in RCC and could therefore be favorable to the
development of RCC tumors.
Correlation between Tensin expression and clinical
variables in RCC patients
We performed correlation analyses to evaluate a potential
relation between Tensin mRNA expression in RCCs and the
clinical characteristics of the patients. The most relevant
correlations are summarized in Table 2. Firstly, mRNA expression
of Tensins 1–3 in tumors correlated positively with each other,
though not with Tensin4 as it was largely undetectable in RCC
samples. No significant correlation was apparent between Tensins
mRNA expression levels and clinical variables as tumor size,
tumor venous infiltration, regional lymph node infiltration, age or
gender. However, there was a notable negative correlation
between tumor grade and both Tensin1 and Tensin3 expression
in tumors, ie. low expression correlated with a high tumor grade.
Similarly, despite a lack of significance, a trend towards a negative
correlation was apparent for tumor grade vs Tensin2 and Tensin4
mRNA expression in tumors.
Immunohistochemical characterization of Tensin3
expression in kidney tumor tissue microarrays (TMA)
Owing to its higher and more prevalent expression in the
kidney, we investigated Tensin3 expression additionally by
immunohistochemical analysis of RCC sections in TMA format.
We found that Tensin3 protein was expressed in the normal
human kidney cortex and is clearly restricted to proximal tubular
epithelial cells, whilst being absent or negligible in glomeruli and
podocytes (Figure 3A). This was in contrast to Tensin2, which
appeared to be present primarily in podocytes in the mouse [15].
Figure 1. Absence of expression of Tensin2 and Tensin3 at both mRNA and protein levels in several different human cancer cell
lines. (A) Northern blot analysis of Tensin2 (TNS2) mRNA in human cancer cell lines. A human cancer cell lines MTN blot was probed at high
stringency with radiolabeled cDNA specific for Tensin2. Lanes are as follows: 1, promyelocytic leukemia HL-60; 2, HeLa S3; 3, chronic myelogenous
leukemia K-562; 4, lymphoblastic leukemia MOLT-4; 5, Burkitt’s lymphoma Raji; 6, colorectal adenocarcinoma SW480; 7, lung carcinoma A549 and 8,
melanoma G-361. The same membrane was also probed for human b-actin (lowest panel) to show equal RNA loading. A representative blot is shown
of two independent hybridizations. (B) mRNA expressions of Tensin2 and Tensin3 analyzed by qRT-PCR. A panel of human cancer cell lines as well as
human normal epithelial and endothelial cell lines were screened for Tensin2 (TNS2) expression (left axis, empty bars) and Tensin3 (TNS3) expression
(right axis, black bars). Results are presented as relative expression given after normalization of gene of interest to reference gene GAPDH (ng gene of
interest/ng reference gene). (C, D) Expression of Tensin2 and Tensin3 proteins in human cancer cell lines. Whole cell lysates were subjected to 8%
SDS-PAGE and western blot detection of Tensin2 and Tensin3 proteins. Lanes are as follows: 1, HEK 293 cells stably transfected with Tensin2 (C); 1,
HEK 293 cells stably transfected with Tensin3 (D) 2, renal carcinoma SKRC-52; 3, HeLa S3; 4, colorectal adenocarcinoma SW480; 5, breast
adenocarcinoma MCF-7; 6, prostate carcinoma DU145; 7, melanoma WM793; 8, lung carcinoma H727.
doi:10.1371/journal.pone.0004350.g001
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sections was found in the cytoplasm and at varying intensities.
There was no Tensin3 expression in the fibrovascular stroma or
endothelial cells of tumour vessels. Positive staining was typified by
a granular, dotted brown staining throughout the cytosol. Out of a
total of 148 patients with RCC tumor sections analyzed, 61 (41%)
displayed either no Tensin3 staining or very weak cytoplasmic
staining. In contrast, a subset of sections (16) showed an additional
strong and defined Tensin3 immunoreactivity at the plasma
membrane. Separating the data according to tumor type, no
significant correlation was apparent between Tensin3 staining
intensity and patient survival (data not shown). However, in
ccRCC patients, presence of Tensin3 staining at the plasma
membrane of positive cells (PM) conferred a statistically significant
survival advantage over those ccRCC tumors with only cytoplas-
mic expression (Figure 3B). Moreover, Tensin3 PM staining in
tumor TMAs tended to correlate negatively with the kidney tumor
stage according to the TNM system (P=0.068), as well as tumor
size (P=0.125; data not shown). In keeping with the TMA results,
tumor Tensin3 mRNA expression in RCC patients was signifi-
cantly correlated with tumor grade in a negative manner, where
decreased Tensin3 mRNA levels were associated with a higher
tumor grade (n=215; P=0.0471; Figure 3C).
Overexpression of Tensin3 in human kidney cells does
not affect proliferation but markedly reduces cell
migration and invasion
Individual clones of HEK 293 cells stably transfected with
empty vector (mock), wildtype Tensin3 or PTPase mutant Tensin3
were generated. These were first verified for expression (or lack
thereof) of Tensin3 by western blot (Figure 4A). Stable expression
of Tensin3 in these cells did not affect their proliferation rates in
serum as compared to mock-transfected cells (Figures 4B and 4C).
However, Tensin3 expression caused greatly reduced rates of both
haptotactic migration (towards an extracellular matrix gradient)
and invasion of basement membrane matrix, as compared with
mock cells (Figure 5). After 18 h of incubation, no cell migration
through 8 mm pores had occurred in the absence of a fibronectin
layer on the other side of the membrane (Figure 5A). However, in
the presence of a fibronectin gradient, each clone of Tensin3 wt
and Tensin3 mutant cells displayed a migration rate at least 50%
lower than that of the mock cell clones (Figure 5A). Therefore,
Figure 2. Downregulation of Tensins 1–4 mRNA expression in human kidney cancer. (A,C) mRNA levels of Tensin2 (TNS2) and Tensin3
(TNS3), respectively in 223 RCC patients grouped according to tumor type, vs normal kidney cortex samples from 48 patients. Results are presented
as relative expression (ng Tensin2/ng B2M and ng Tensin3/ng B2M, respectively). Tensin2 and Tensin3 expression in relation to tumor type as well in
control group are shown along with the median value.
***P,0.001 normal vs. papillary and for normal vs. ccRCC. (B,D) mRNA levels of Tensin1 (TNS1)
and Tensin4 (TNS4), respectively in 134 RCC cases (tumor) and 21 kidney cortex samples (normal) after normalization to reference gene (relative
expression). Medians are shown for both Tensin1 and Tensin4 expression in normal and tumor samples. In panel D, the value n=123 is indicated as
the number of tumor samples with no Tensin4 expression.
***P,0.001 normal vs. tumor.
doi:10.1371/journal.pone.0004350.g002
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phosphatase-dead version of Tensin3 did not hinder Tensin3
from this suppressive effect. In addition, Tensin3 expression also
inhibited the capacity of 293 cells to invade through a basement
membrane matrix towards a serum gradient, which was also
apparent in cells expressing mutant Tensin3 (Figure 5B).
Gene silencing of endogenous Tensin3 in human cancer
cells by siRNA increases their migration
Due to fact that overexpression of Tensin3 in 293 cells markedly
reduced cell migration, we performed siRNA knockdown
experiments to investigate the role of endogenous Tensin3 in
migration of a human primary cancer cell line. The human
melanoma cancer cell line WM793 was chosen due to its high
endogenous expression of Tensin3 relative to other cancer cell
lines (Figure 1B). Converse to the inhibitory effect of overexpress-
ing Tensin3 in normal cells, WM793 cells showed an increased
migration when treated with specific siRNA for Tensin3 (Figure 6).
We utilized three separate, validated siRNA constructs to
knockdown endogenous Tensin3, and all three were effective in
reducing Tensin3 mRNA expression by at least 50% in
comparison to negative controls (Figure 6A). This knockdown of
Tensin3 by all three siRNAs was also observed at the protein level
by western blotting (Figure 6B). The silencing of endogenous
Tensin3 by each of the three siRNAs caused a significant increase
(30%) in haptotactic migration of WM793 cells as compared to
non-silenced controls (Figure 6C). Thus, suppression of endoge-
nous Tensin3 expression enhances cancer cell migration, in
keeping with the converse effects seen with ectopic expression.
Discussion
Despite advances in research that have identified molecular
triggers for RCC, such as dysfunction of the VHL tumor
suppressor gene, the picture is far from complete and there is a
need to further define the pathogenesis of RCC and identify
potential targets for therapy. The predicted five-year survival rate
for RCC patients at all stages is 67% [13], 47% in patients with
renal involvement [24], and only 10% in patients with stage IV
disease (metastasis) [13]. Furthermore, most of advanced RCC
patients do not respond to standard cytokine therapy [25] and the
novel tyrosine kinase inhibitors generally only stabilize the disease
[26]. This therefore makes urgent the need for novel therapies
particularly aimed at treating metastatic disease.
Today there exist dozens of intracellular molecules, the loss of
which are associated with the neoplastic state in cells. This study is
the first comprehensive investigation of the Tensin family of
intracellular proteins in human kidney cancer, and moreover in
human clinical disease. We have studied all four members of the
Tensin family and, in keeping with a proposed tumor/metastasis
suppressor role, found them all to be reduced in expression in
RCC. Tensins -2 and -3 were absent or barely expressed in a
variety of human cancer cell lines. Furthermore, a preferential
plasma membrane expression of Tensin3 was correlated with
greater survival. In addition, recombinant Tensin3 expression in
Table 2. Correlation between mRNA expressions of Tensins 1–4 (TNS1-4) in RCC patients and various clinical variables.
TNS1 mRNA in tumor TNS2 mRNA in tumor TNS3 mRNA in tumor TNS4 mRNA in tumor
Tumor grade (1) 20.196 20.107 20.115 20.131
(2) 0.026* 0.116 0.023* 0.136
(3) 129 215 215 131
Tumor size 0.089 20.063 20.069 20.005
0.308 0.350 0.304 0.952
134 223 223 134
Venous invasion 0.001 20.055 20.064 20.102
0.994 0.417 0.341 0.242
134 223 223 134
Regional lymph node involvement 20.022 20.138 0.016 0.281
0.888 0.229 0.892 0.068
44 78 78 43
TNS1 mRNA in tumor - 0.555 0.342 0.074
- ,0.001*** ,0.001*** 0.529
- 134 134 74
TNS2 mRNA in tumor 0.555 - 0.515 0.199
,0.001*** - ,0.001*** 0.021*
134 - 223 133
TNS3 mRNA in tumor 0.342 0.515 - 0.075
,0.001*** ,0.001*** - 0.394
134 223 - 133
TNS4 mRNA in tumor 0.074 0.199 0.075 -
0.529 0.021* 0.394 -
74 133 133 -
(1) r value, significant values in bold;( 2 )P value; (3) number of cases; *P,0.05; ***P,0.001.
doi:10.1371/journal.pone.0004350.t002
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PLoS ONE | www.plosone.org 7 February 2009 | Volume 4 | Issue 2 | e4350Figure 3. Presence of immunohistochemical staining of Tensin3 at the plasma membrane correlates with increased patient survival.
(A) Photomicrographs of normal human kidney (upper left) and ccRCC sections (remaining; 36higher magnification), showing differential staining
patterns for Tensin3: low (upper right), high (lower left) and additionally at the plasma membrane (PM; indicated by arrows; lower right). In normal
human kidney, Tensin3 staining is present almost exclusively in proximal tubular epithelium (T) and is characterized by a granular brown staining
Tensins in Human Kidney Cancer
PLoS ONE | www.plosone.org 8 February 2009 | Volume 4 | Issue 2 | e4350human kidney cells caused a greatly reduced haptotactic cell
migration and matrix invasion, indicating a role for Tensins in
control of cell motility.
Our quantitative RT-PCR, western blot and immunohisto-
chemistry results indicate that Tensin3 and Tensin1 are likely the
most prevalent Tensins in the human kidney. Tensin3 is expressed
preferentially in renal proximal tubular epithelium, while Tensin2
may also be present in podocytes [15], although Tensin2 is
expressed at a lower level in total. All four Tensins were found to
be highly significantly lower or absent in RCC tissue versus
matched normal kidney cortex tissue. Notably, Tensin3 gene
expression was significantly negatively correlated with tumor
grade. The significance of the expression of Tensin3 and its loss in
tumor development has been reported for breast cancer cells,
where Tensin3 downregulation was coupled to lesser cytoskeletal
stability and consequently greater motility [9]. Downregulation of
Tensin3 in thyroid tumors was also shown [27]. Tensin2
downregulation in tumourigenesis has been observed in hepato-
cellular carcinoma [28] and uterine carcinoma [29]. This is the
first observation of a downregulation of Tensin1 in human cancer,
and may also be relevant, as it has previously been shown that
genetic deletion of Tensin1 in mice causes renal dysfunction [17].
In the case of Tensin4, this Tensin has been observed at both
higher [9,30,31] and lower [8] levels in different clinical tumor
samples. One study has reported results indicating that Tensin4
may compete with Tensin3 in sites where it is expressed strongly
enough [9]. However, in our study we found Tensin4 to be the
least expressed of all the Tensins in human kidney, and it was in
fact absent in most RCCs analyzed. Moreover, all the Tensins are
able to interact with DLC-1 tumor suppressor protein, and may
Figure 4. Stable expression of Tensin3 in HEK 293 cells and effect on proliferation. (A) Western blot analysis of recombinant Tensin3
expression in individual stable HEK 293 cell clones. Cell lysate proteins were separated by 5% SDS-PAGE, followed by western blotting with an anti-
human Tensin3 antibody and chemiluminescent development. Three clones of mock cells (M1-3), 3 of wildtype Tensin3 cells (T1-3) and 2 of mutant
Tensin3 cells (CS1-2) were analyzed. The upper bands correspond to expected size of Tensin3; lower bands are non-specific immunoreactivity, which
is present in all cell extracts. (B) Proliferation of stable Tensin3-expressing cells by measurement of viable cell number through mitochondrial activity.
Equal numbers of mock cells, wildtype Tensin3 cells (Tns3 wt) and Tensin3 PTPase mutant cells (Tns3 Mut) were incubated in medium containing 5%
fetal calf serum. On days 1–7, conversion of MTS into soluble formazan during 3 h by viable cells was measured spectrophotometrically at 490 nm.
Points represent the fold difference in Abs490 compared to that on day 1 (quadruplicate wells per measurement). Results are mean6SEM (n=5
separate experiments, pooling results from 3 mock cell clones vs 3 Tns3 wt cell clones vs 2 Tns3 Mut cell clones). All cell types grew at similar rates,
and there was no statistical difference between cell types on each day (ANOVA). (C) Growth curves of stable Tensin3-expressing cells by measurement
of absolute cell number. Equal numbers of mock cells, wildtype Tensin3 cells (Tns3 wt) and Tensin3 PTPase mutant cells (Tns3 Mut) were incubated in
medium containing 5% fetal calf serum. On days 1–5, cells were trypisinized and counted on a cell counting chamber. Points represent the fold
difference in cell number compared to that on day 1. Results are mean6SEM from two pooled separate experiments, comparing 3 mock cell clones vs
3 Tns3 wt cell clones vs 2 Tns3 Mut cell clones. All cell types grew at similar rates, and there was no statistical difference between cell types on each
day (ANOVA).
doi:10.1371/journal.pone.0004350.g004
within the cytosol, while being absent in the glomerulus (G). Whole scale bar represents 15 mm, while dotted scale bars are 5 mm. (B) Kaplan-Meier
plot illustrating survival curves of 88 patients with clear cell RCC tumors displaying Tensin3 staining in the cytoplasm (n=72) and also at the plasma
membrane (PM, n=16). (C) A box plot of Tensin3 (TNS3) mRNA level in relation to tumor grade (n=215).
*P,0.05, statistical significance in Tensin3
expression over range of tumor grades (Kruskal-Wallis test).
doi:10.1371/journal.pone.0004350.g003
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Therefore, all together these results indicate that a general loss of
Tensins may be advantageous to the development or spread of
tumors.
The immunohistochemical analysis of Tensin3 protein expres-
sion and localization in RCC, using TMAs, showed an interesting
negative correlation between its plasma membrane localization
and patient survival. This indicates that in ccRCC patients where
tumor cells have Tensin3 present at the plasma membrane have a
better survival prognosis than ccRCC patients lacking Tensin3 or
expressing it only within the cytoplasm. In keeping with data
supporting the necessity of Tensin3 for cytoskeletal stability and
organization [9], observation of Tensin3 at the cell periphery may
indicate that a tumor cell is more static and thus less likely to be
motile and metastasize.
We investigated the biological role of Tensin3 in various cell
models. Normal kidney cells were stably transfected with both wild
type Tensin3 as well as a Tensin3 mutant that would potentially
abolish any phosphatase activity. Stable expression of Tensin3 did
not affect cell viability and proliferation; however, it affected both
cell migration and invasion negatively. Tensin3-expressing cells
exhibited a markedly reduced migration towards a fibronectin
gradient as compared to mock-transfected cells. Furthermore,
expression of a putative phosphatase-dead Tensin3 also inhibited
migration to the same degree, indicating that the effect is
independent of a phosphatase activity in the protein. In addition,
Tensin3 also markedly reduced invasion of these cells into a
basement membrane matrix. Moreover, we observed the opposite
effect, i.e increased cell migration, using siRNA to knock down
endogenous Tensin3 in human cancer cells. These results
demonstrate that Tensin3 stabilizes cells and prevents their
uncontrolled migration under normal conditions. However, loss
of Tensin3, as occurs in e.g. RCC and other cancers, may underlie
the increased cell motility in cancer cells and their propensity to
subsequently metastasize, as has been alluded to previously [9].
Furthermore, any putative PTEN-like phosphatase activity in
Tensin3 is not necessary for this potential anti-metastatic capacity
of Tensin3. We have previously characterized the function of
Tensin2 in kidney cells and found Tensin2 to suppress the Akt
signaling pathway as well as inhibit cell proliferation, survival and
migration [5]. Moreover, Tensin1 null cells have also been shown
to exhibit impaired migration [32]. Taken together, it is therefore
likely that the cell motility modifying capacity of all Tensin family
members is a common feature relying on their integrin/
cytoskeletal interactions. In contrast, Akt pathway suppression
may be unique amongst those members of the Tensin family that
may have a lipid phosphatase activity, ie potentially only Tensins -
2 and -3, and may be linked to cell survival and proliferation.
Much still remains to be uncovered as to the range of functions
various tumor suppressors play. Understanding the biological
characteristics of individual tumor suppressors and their relation to
specific diseases will certainly provide new avenues in the future
for screening, diagnosis and treatment. Studies on Tensins so far
including the present one indicate that the Tensins represent a
unique family of intracellular proteins that are able to link the
extracellular matrix, via integrins and cell surface receptors, to the
cytoskeleton and thereby control cytoskeletal organization and
consequent migratory capacity of cells. This feature may be
necessary for maintenance of normal cell architecture, and when
disrupted, for example after long-term stimulation by growth
factors, would result in cellular instability and greater motility. The
ensuing cell behavior would thus be expected to favor the
metastatic process.
We have shown that the expression of all Tensins is
downregulated inRCC, and therefore analyzing gene expression
and/or subcellular localization of one or more of the Tensins
could be useful complements for diagnostic and prognostic
estimations. The present study further suggests the potential value
of therapies aimed at potentiating or upregulating the Tensins as
an anti-metastatic strategy. This is already a prospect with existing
agents under trial, such as the cancer chemopreventative
polyphenol resveratrol, which was shown to markedly upregulate
Tensin1 in different cancer cell lines [33].
Supporting Information
Figure S1 Anti-Tensin3 antibody. Polyclonal anti-Tensin3
(Tns3) antibody was verified for specificity by antigen blocking.
Antibody was incubated overnight at the optimal dilution of 1:300
either alone (A), or together with the peptide antigen it was raised
against (Ag; B), or with the recombinant phosphatase domain of
Tns3 (PTPase, negative control, C). Potential immune complexes
were removed by centrifugation, followed by immunohistochem-
ical testing of the mixtures on normal human kidney section as
described (Methods). Bar represents 15 micrometers. Note that
Tns3 immunoreactivity is completely blocked by the relevant
antigen (B) but not by an irrelevant antigen from the same protein
(C).
Found at: doi:10.1371/journal.pone.0004350.s001 (6.65 MB PPT)
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Figure 5. Tensin3 expression inhibits haptotactic HEK 293 cell migration as well as their invasion through extracellular matrix. (A)
Migration assay. Equal numbers of HEK 293 cells stably transfected as mock, wildtype Tensin3 (Tns3 wt) and PTPase mutant Tensin3 (Tns3 Mut) were
allowed to migrate towards fibronectin in cell culture inserts for 18 h at 37uC. The upper panel shows light micrographs of the undersides of the
chambers showing cells that had migrated to the lower side of the membranes and stained with crystal violet. Chambers shown are those with mock
cells but no fibronectin (2Fn, upper left; only pores are visible), mock cells (upper right), Tns3 wt (lower left), and Tns3 Mut (lower right). The lower
panel is a quantitative representation of the migration of individual stable transfected cell clones: mock cells (M1-3), wildtype Tensin3 cells (T1-3) and
Tensin3 PTPase mutant cells (CS1-2) (characterized in Figure 4A). Each bar represents mean6SD migrated cells (n=6 fields counted per insert,
duplicate inserts per clone). *** denotes P,0.001 for each mock cell clone vs each of the Tns3 clones (AVONA with Bonferroni adjustment). (B)
Matrigel invasion assay. Equal numbers of HEK 293 cells stably transfected as mock, wildtype Tensin3 (Tns3 wt) and PTPase mutant Tensin3 (Tns3
Mut) were allowed to migrate through a Matrigel layer on top of a cell culture insert membrane over 30 h at 37uC. As for migration assay, cells on the
lower side of the membranes at 30 h were fixed, stained with crystal violet and counted. Bars represent mean6SEM number of invaded cells (n=3
cell clones per type (2 for Tns3 Mut); duplicate inserts per clone; 6 fields counted per insert). *** denotes P,0.001 for mock cells vs Tns3 wt and Tns3
Mut cells (ANOVA with Bonferroni adjustment).
doi:10.1371/journal.pone.0004350.g005
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PLoS ONE | www.plosone.org 11 February 2009 | Volume 4 | Issue 2 | e4350Figure 6. siRNA knockdown of endogenously expressed Tensin3 in human melanoma cells increases cell migration. Endogenous
Tensin3 expression was knocked down over 24 h in human melanoma cells WM793 using three different Tensin3 siRNA constructs (siRNA I, II, III), as
well as non-silencing siRNA and transfection mixture only (negative controls). (A) mRNA level of Tensin3 in WM793 cells after 24 h gene silencing,
analyzed by qRT-PCR. Results of gene expression were normalized to endogenous control gene (B2M) and are presented as Tensin3 (TNS3) expression
relative to non-silenced control (transfection mix only; first bar). Bars shown are means of duplicate determinations from a representative experiment
of four. (B) Protein level of Tensin3 (TNS3) in WM793 cells after 24 h gene silencing, analyzed by western blot. Whole cell lysates were subjected to 8%
SDS-PAGE and western blot detection with anti-Tensin3 antibody. Band intensities were quantified by densitometry and normalized to GAPDH
protein level on the same blot. Bars are Tensin3 protein expression relative to non-silenced control (transfection mix only; first bar). (C) Migration of
WM793 cells over 16 h, treated with different siRNA constructs as well as negative controls (transfection mix only, and non-silencing siRNA). Each bar
represents mean6SEM migrated cells expressed as fold difference relative to negative control cells (transfection mix only) (n=3 separate
experiments, duplicate inserts). ***P,0.001 control vs. Tensin3 siRNA II; **P,0.01 control vs. Tensin3 siRNA I and III; no significant difference for
control v non-silencing siRNA (ANOVA with Bonferroni adjustment).
doi:10.1371/journal.pone.0004350.g006
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